Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ST18 antisense RNA 3 (ST18-AS3) likely refers to a putative non-coding RNA transcribed from the DNA strand opposite the ST18 protein-coding gene. Antisense RNAs are typically involved in the regulation of gene expression, often by hybridizing with the sense (mRNA) transcript to affect its stability or translation. However, as of this review, there is no substantive characterization of ST18-AS3 in the literature, and no established function, disease association, or druggability. Most research pertains to the ST18 protein, a zinc finger transcription factor involved in regulating apoptosis and inflammation. Thus, ST18-AS3 is not presently recognized as a therapeutic target. Key points: - The entry may be incorrect or excessively speculative as a molecular target. - There is no robust evidence for its function, disease roles, or druggability. - Remove or replace with "ST18" (the transcription factor) if a protein-coding target is intended.
Not established; general mechanism for antisense RNAs includes hybridization to complementary mRNA to inhibit translation or modulate stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ST18 antisense RNA 3 (ST18-AS3).